Document Detail


Treatment update in small-cell lung cancer: from limited to extensive disease.
MedLine Citation:
PMID:  23139116     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Small-cell lung cancers are aggressive tumors, often discovered with widespread metastases that include brain involvement. For patients with limited-stage disease, the standard of care is platinum-doublet chemotherapy (often etoposide) with concurrent radiation. Concurrent chemoradiotherapy can be difficult when given upfront, sometimes preventing on-time completion of later chemotherapy cycles. Recent data support giving concurrent chemoradiotherapy following 1 or 2 cycles of chemotherapy alone. For patients with extensive disease, chemotherapy alone remains the standard of care. For patients with limited or extensive disease who achieve clinical benefit from primary therapy, consideration of prophylactic cranial radiation should be made. Despite aggressive use of these treatments, most patients will have life-threatening disease return, sometimes very soon after finishing treatment. For those patients who are candidates for additional systemic treatment, several single-agent options exist, such as topotecan, paclitaxel, or even consideration of retreating with the same initial regimen depending on how effective it was. All patients with SCLC should be considered for clinical trials, because this remains our greatest hope for finding more effective therapies.
Authors:
David R Spigel
Related Documents :
23049216 - Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomogra...
24078886 - Efficacy of the radiotherapy on darier's disease: an indirect evidence.
24563786 - Primary synovial sarcomas of the mediastinum: a systematic review and pooled analysis o...
16627756 - Survival advantage from imatinib compared with the combination interferon-alpha plus cy...
21116626 - Adjuvant and neoadjuvant therapy for primary gist.
3179946 - Cisplatin and mitoguazone. an induction chemotherapy regimen in advanced head and neck ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in oncology     Volume:  13     ISSN:  1534-6277     ISO Abbreviation:  Curr Treat Options Oncol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-05-24     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  100900946     Medline TA:  Curr Treat Options Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  505-15     Citation Subset:  IM    
Affiliation:
Lung Cancer Research Program, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA. david.spigel@scresearch.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols*
Carcinoma, Small Cell* / drug therapy,  pathology,  radiotherapy
Cisplatin / administration & dosage
Clinical Trials as Topic
Combined Modality Therapy
Etoposide / administration & dosage
Humans
Lung Neoplasms* / drug therapy,  pathology,  radiotherapy
Neoplasm Metastasis
Neoplasm Staging
Paclitaxel / administration & dosage
Small Cell Lung Carcinoma* / drug therapy,  pathology,  radiotherapy
Topotecan / administration & dosage
Chemical
Reg. No./Substance:
123948-87-8/Topotecan; 15663-27-1/Cisplatin; 33069-62-4/Paclitaxel; 33419-42-0/Etoposide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  [Estimate of the spatial variability of exposure to airborne pollutants in urban areas].
Next Document:  Blood-derived stem cells (BDSCs) plasticity: In vitro hepatic differentiation.